EDGC Rises 7.35% Amid Uptrend in COVID-19 (Diagnosis/Treatment/Vaccine Development) Theme

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.77% compared to the previous day, showing strength, while EDGC, a related stock drawing attention, surged by 7.35% compared to the previous day. EDGC is known as a genome analysis specialized company.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, EDGC’s quant financial score is 3.73 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (diagnosis/treatment/vaccine development, etc.). This can be interpreted as EDGC having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, United Pharm ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialized company Thinkpool.

This content was produced with the assistance of AI translation services.